Streetbeat News

Regulatory

NVS

Health Canada has approved Innodem Neurosciences' Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS), a class II software as a medical device (SaMD) for tracking disease progression in MS patients by providing an EDSS score between 1.0 and 4.5.

Portfolio Pulse from Charles Gross

March 25, 2024 | 9:15 pm

AMPE

Ampio Pharmaceuticals has announced its intention to voluntarily delist its shares of common stock from the NYSE American and proceed with SEC deregistration.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 9:13 pm

CLF

RIO

X

Cleveland-Cliffs (NYSE:CLF) is set to receive up to $575 million from the U.S. Department of Energy for decarbonization projects in Ohio and Pennsylvania, aiming to significantly reduce carbon intensity in steel production. This move, part of a broader shift towards renewable energy steelmaking, positions Cleveland-Cliffs as a leader in the industry. The projects are expected to save $450 million annually in production costs, preserve 2,500 jobs, and create additional jobs. This initiative is supported by strong government backing and could enhance Cleveland-Cliffs' position in the domestic steel sector amidst Nippon Steel's acquisition of U.S. Steel (NYSE:X) and political interest in supporting the domestic industry.

Portfolio Pulse from Stjepan Kalinic

March 25, 2024 | 8:58 pm

VFF

Germany's recent legalization of cannabis has positioned Village Farms International, Inc. (NASDAQ:VFF) as a key player in the expanding European market. With its EU GMP certification and successful shipments of Canadian strains to Germany, Village Farms is capitalizing on the growing German market, projected to reach €1.7 billion by 2025. The company's strong performance, highlighted by record fourth-quarter sales and an attractive valuation, underscores its operational efficiency and strategic focus on Europe.

Portfolio Pulse from Jelena Martinovic

March 25, 2024 | 8:52 pm

AGRX

Agile Therapeutics shares are trading lower following the announcement that its trading on the Nasdaq will be suspended effective March 26.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:49 pm

STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q4 financial results, beating the analyst consensus on EPS with losses of 60 cents per share but missing on sales with $2.8 million. The company announced positive Phase 1/2a study data for STK-001 in treating Dravet syndrome, showing significant reductions in seizure frequency and cognitive improvements. The FDA has cleared STK-001 for increased dosing. Shares surged 71.08% after-hours to $11.12.

Portfolio Pulse from Erica Kollmann

March 25, 2024 | 8:40 pm

AGRX

Agile Therapeutics has received a final delisting notice from Nasdaq, with its common stock to be suspended from trading on March 26, 2024. Post-delisting, the stock will be available for trading on the OTC Market.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:31 pm

TIRX

TIAN RUIXIANG Holdings has been notified by Nasdaq about non-compliance due to the late filing of its annual report on Form 20-F. This notification could impact the company's listing status if the issue is not resolved in a timely manner.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:31 pm

FSR

The New York Stock Exchange (NYSE) has announced it will start delisting proceedings against Fisker, leading to an immediate suspension of trading in the company's Class A common stock.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:27 pm

AMRX

Amneal Pharmaceuticals has received FDA approval for its Ciprofloxacin and Dexamethasone Otic Suspension, a product that references the branded Ciprodex. This approval represents the addition of another complex, high-value product to Amneal's portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:13 pm